Navigation Links
Cepheid Reports 2013 First Quarter Results
Date:4/18/2013

loss) per share 

$
.00$
(0.08)Diluted net income (loss) per share 

$
.00$
(0.08)Shares used in computing basic net income (loss) per share 

66,82465,02769,40665,027Shares used in computing diluted net income (loss) per share CEPHEIDCONDENSED CONSOLIDATED UNAUDITED BALANCE SHEETS(in thousands)March 31, 2013December 31, 2012ASSETSCurrent assets:Cash and cash equivalents

$
,988$
95,779Accounts receivable, net

45,04643,999Inventory

78,23970,114Prepaid expenses and other current assets 

12,9079,448Total current assets

238,180219,340Property and equipment, net

59,99054,830Other non-current assets

745913Intangible assets, net

18,20718,767Goodwill

37,66037,694Total assets

$
354,782$
331,544LIABILITIES AND SHAREHOLDERS' EQUITYCurrent liabilities:Accounts payable 

$
43,466$
33,701Accrued compensation 

15,92616,540Accrued royalties 

6,8597,992Accrued and other liabilities 

3,4724,235Current portion of deferred revenue

12,3549,599Current portion of notes payable

186183Total current liabilities 

82,26372,250Long-term portion of deferred revenue

1,0091,156Notes payable, less current portion

1,6411,685Other liabilities

8,5798,911Total liabilities

93,49284,002Shareholders' equity:Common stock

362,012355,867Additional paid-in capital 

123,806117,217Accumulated other comprehensive income

75756Accumulated deficit 

(225,285)(225,598)Total shareholders' equity 

261,290247,542Total liabilities and shareholders' equity 

$
354,782$
331,544 CEPHEIDCONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF CASH FLOWS(in thousands)Three Months Ended
March 31, 20132012Cash flows from operating activities:Net income (loss)<
'/>"/>

SOURCE Cepheid
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Testing Positive for Stability & Growth - Research Report on CombiMatrix Corporation, Cepheid, PerkinElmer, Inc., Life Technologies Corp. and Laboratory Corp. of America Holdings
2. Cepheid Announces Board of Directors Changes
3. Cepheid Reports 2012 Second Quarter Results
4. Cepheid Receives FDA Clearance for GeneXpert Infinity-80 System for Initial Use with Xpert Flu Assay
5. Cepheid Announces European Release of Xpert CT/NG and Xpert CT, Delivering Rapid Detection and Differentiation of Chlamydia and Gonorrhoeae
6. Diagnostic Marketing Association Names Cepheid 2011 Marketer of the Year
7. Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria
8. Cepheid to Webcast Upcoming Financial Presentations
9. Cepheid Reports Fourth Quarter and Full Year 2011 Results
10. Cepheid Welcomes Senior Vice President of Human Resources
11. Global Nano-Materials Market 2002-2016: Nano-Materials Industry, Production Volumes, Revenues and End User Market Demand - MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... mája 2015 Kevin Xu , ... prezidentom Barackovi Obamovi a Billovi Clintonovi za ich ... Dr. Rongxiang Xu , otca Kevina. ... Dr. Xu bol pionier, inovátor, humanitárny pracovník ... v oblasti vedy a príkladné vedenie svojej komunity ...
(Date:5/26/2015)... May 26, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that all outstanding common ... exercised prior to their expiry on June 15, 2015, ... million. "We thank our shareholders for their ... CEO of Asterias. "This exercise of warrants represents a ...
(Date:5/26/2015)... /PRNewswire/ - Fluorinov Pharma (Fluorinov), a FACIT portfolio company, ... to its Board of Directors.  His appointment strengthens ... as Fluorinov accelerates its clinical development activities.  ... a pleasure to welcome Luke to the Board of ... strategy, financial strength and success of multiple organizations," said ...
(Date:5/26/2015)... YORK , May 26, 2015 US-Australian drug discovery ... today that it will present at the 2015 Marcum MicroCap ... York City at the Grand Hyatt Hotel. ... Chairman and CEO, is scheduled to begin at 9.30 a.m. ET ... webcast, go to http://wsw.com/webcast/marcum3/nvgn . The annual ...
Breaking Biology Technology:Dr. Rongxiang Xu, O legende 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 2Asterias Biotherapeutics Receives $11.7 Million in Proceeds from Exercise of Warrants 3Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 2Luke M. Beshar Appointed to Fluorinov Pharma Board of Directors 3Novogen to Present at the 2015 Marcum Microcap Conference 2Novogen to Present at the 2015 Marcum Microcap Conference 3Novogen to Present at the 2015 Marcum Microcap Conference 4
... ORLANDO, Fla. , June 26, 2010 ... Eli Lilly and Company (NYSE: LLY ) ... more than 260,000 patients that showed the risk of ... not increased compared to initiators of other antidiabetic therapies. ...
... we will use our mobile phone to buy bus and ... other European states by just presenting an electronic card or ... Most of us hate standing in queues or filling ... signatures could save hours of our time running to offices ...
... NEW YORK , June 25 /PRNewswire-Asia-FirstCall/ -- ... an international biopharmaceutical,company with operations in the U.S. and ... agreements with certain accredited,investors (the "Investors") to sell in a ... of $5 million . Each unit was,priced at ...
Cached Biology Technology:Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 2Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 3Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 4Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 5Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 6Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 7Study Finds BYETTA(R) Use Was Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs: Final Results Presented at ADA 2010 8Really smart card project scoops EUREKA 2010 Innovation Award 2Really smart card project scoops EUREKA 2010 Innovation Award 3Really smart card project scoops EUREKA 2010 Innovation Award 4NeoStem Raises $5 Million in Registered Direct Offering 2NeoStem Raises $5 Million in Registered Direct Offering 3NeoStem Raises $5 Million in Registered Direct Offering 4
(Date:4/27/2015)... Profile Solutions, Inc. (OTC: PSIQ), a leading ... pleased to announce that Dr Gerry Bedore ... of its scientific advisory board. ... leader in technology-enhanced learning models. He was a co-founder ... studies and books focused on online student success and ...
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/9/2015)... April 9, 2015 Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 2015, after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
Breaking Biology News(10 mins):Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2
... ulcerative colitis, according to a new study co-ordinated by medical ... Presented today at the Digestive Disease Week conference in New ... in oleic acid which is present in olive oil ... is a monounsaturated fatty acid found in olive oil, peanut ...
... during pregnancy is not only safe for mother and baby, ... results of a randomized controlled study to be presented at ... Columbia, Canada. In the 1950s and ,60s, people ... to Carol L. Wagner, MD, lead author of the study ...
... KY Current research suggests that tumor-secreted exosomes ... related report by Liu et al, "Contribution of MyD88 ... cells," appears in the May 2010 issue of ... system plays a critical role in identifying and destroying ...
Cached Biology News:Olive oil could guard against developing ulcerative colitis 2Researchers recommend pregnant women take 4,000 IU vitamin D a day 2
Anti-ZFP-38/RU49 Family: Zinc Finger Peptide Sequence: SVKVEDKDFPSTCSKK...
TRIzol Reagents are ready-to-use monophasic solutions of phenol and guanidine isothiocyanate suitable for isolating total RNA DNA and proteins (16)....
Antibodies were affinity purified using epitopes specific to UBAP2L/NICE4 immobilized on solid support....
... Biochain's plant total protein western ... rapidly screening tissue specific protein ... placenta total protein is included ... interblot control for comparison between ...
Biology Products: